APA (7th ed.) Citation

JT, W., CL, T., HF, T., PH, K., YC, C., YJ, C., . . . SS, L. (2025). HCB101: A novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors. Journal of hematology & oncology, 18(1), 87. https://doi.org/10.1186/s13045-025-01742-x

Chicago Style (17th ed.) Citation

JT, Wang, et al. "HCB101: A Novel Potent Ligand-trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors." Journal of Hematology & Oncology 18, no. 1 (2025): 87. https://doi.org/10.1186/s13045-025-01742-x.

MLA (9th ed.) Citation

JT, Wang, et al. "HCB101: A Novel Potent Ligand-trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors." Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 87, https://doi.org/10.1186/s13045-025-01742-x.